BAY1238097 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as a selective inhibitor of certain kinases involved in cell signaling pathways that promote tumor growth and survival. By targeting these specific kinases, it aims to disrupt the proliferation of cancer cells and induce apoptosis. Preclinical studies have shown promising results in inhibiting tumor growth in various cancer models, particularly in cases where traditional therapies have limited efficacy. Its application is being explored in combination with other anticancer agents to enhance therapeutic outcomes and overcome drug resistance. Ongoing research focuses on its efficacy, safety profile, and potential use in personalized medicine for patients with specific genetic mutations or cancer types.